Cancer Treatment Reviews
Volume 29, Issue 5 , Pages 407-415 , October 2003

Mode of action of docetaxel – a basis for combination with novel anticancer agents

  • Roy S Herbst

      Affiliations

    • Department of Thoracic/Head and Neck Medical Oncology and Cancer Biology, The University of Texas, Houston, TX, USA
    • ,
  • Fadlo R Khuri

      Affiliations

    • Clinical and Translational Research, Emory University, Atlanta, GA, USA
    • Corresponding Author InformationCorrespondence to: Professor Fadlo R. Khuri, MD, Associate Director, Clinical and Translational Research, Winship Cancer Center, Emory University, 1365 Clifton Road, Suite B4100 Atlanta, GA 30322, USA

References 

  1. Bissery MC. Preclinical pharmacology of docetaxel. Eur. J. Cancer. 1995;31A(Suppl 4):S1–6
  2. Ringel I, Horwitz SB. Studies with RP 56976 (Taxotere): a semisynthetic analogue of taxol. J. Natl. Cancer Inst. 1991;83:288–291
  3. Riou JF, Naudin A, Lavelle F. Effects of Taxotere on murine and human tumor cell lines. Biochem. Biophys. Res. Commun. 1992;187:164–170
  4. Bissery MC, Nohynek G, Sanderink GJ, Lavelle F. Docetaxel (Taxotere®): a review of preclinical and clinical experience. Part I: Preclinical experience. Anticancer Drugs. 1995;6:339–368
  5. Michaud LB, Valero V, Hortobagyi G. Risks and benefits of taxanes in breast and ovarian cancer. Drug Saf. 2000;23:401–428
  6. Crown J, O’Leary M. The taxanes: an update. Lancet. 2000;355:1176–1178
  7. Figgitt DP, Wiseman LR. Docetaxel: an update of its use in advanced breast cancer. Drugs. 2000;59:621–651
  8. Kaye SB and the Scottish Gynaecological Cancer Trials Group. The integration of docetaxel into first-line chemotherapy for ovarian cancer. Int J Gynecol Cancer 2001; 11(Suppl 1): 31–33
  9. Petrylak DP. Docetaxel (Taxotere) in hormone-refractory prostate cancer. Semin. Oncol. 2000;27(Suppl 3):24–29
  10. Posner MR. Docetaxel in squamous cell cancer of the head and neck. Anticancer Drugs. 2001;12(Suppl 1):21–24
  11. Ridwelski K, Gebauer T, Fahlke J, et al.  Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann. Oncol. 2001;12:47–51
  12. Shepherd FA, Fossella FV, Lynch T, Armand JP, Rigas JR, Kris MG. Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: a review of two phase III trials. Semin. Oncol. 2001;28(Suppl 2):4–9
  13. Rowinsky EK, Donehower RC. Antimicrotubule agents. In:  Chabner BA,  Longo DL editor. Cancer chemotherapy and biotherapy. 2nd ed.. Philadelphia: Lippincott-Raven; 1996;p. 263–296
  14. Diaz JF, Valpuesta JM, Chacon P, Diakun G, Andreu JM. Changes in microtubule protofilament number induced by Taxol binding to an easily accessible site. Internal microtubule dynamics. J. Biol. Chem. 1998;273:33803–33810
  15. Andreu JM, Diaz JF, Gil R, et al.  Solution structure of Taxotere-induced microtubules to 3-nm resolution. The change in protofilament number is linked to the binding of the taxol side chain. J. Biol. Chem. 1994;269:31785–31792
  16. Guéritte-Voegelein F, Guénard D, Lavelle F, Le Goff MT, Mangatal L, Potier P. Relationships between the structure of taxol analogues and their antimitotic activity. J. Med. Chem. 1991;34:992–998
  17. Bernard C, Fellous A, Di Leo A, et al.  Evaluation of microtubule associated parameters (MTAPs) as predictive markers for advanced breast cancer (ABC) patients treated with docetaxel. Eur. J. Cancer. 2001;37(Suppl. 6):182
  18. Wang LG, Liu XM, Kreis W, Budman DR. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother. Pharmacol. 1999;44:355–361
  19. Renehan AG, Booth C, Potten CS. What is apoptosis, and why is it important?. BMJ. 2001;322:1536–1538
  20. Schimming R, Mason KA, Hunter N, Weil M, Kishi K, Milas L. Lack of correlation between mitotic arrest or apoptosis and antitumor effect of docetaxel. Cancer Chemother. Pharmacol. 1999;43:165–172
  21. Pratesi G, Perego P, Zunino F. Role of Bcl-2 and its post-transcriptional modification in response to antitumor therapy. Biochem. Pharmacol. 2001;61:381–386
  22. Jansen B, Wacheck V, Heere-Ress E, et al.  Chemosensitisation of malignant melanoma by Bcl-2 antisense therapy. Lancet. 2000;356:1728–1733
  23. Haldar S, Basu A, Croce CM. Bcl-2 is the guardian of microtubule integrity. Cancer Res. 1997;57:229–233
  24. Haldar S, Jena N, Croce CM. Inactivation of Bcl-2 by phosphorylation. Proc. Natl. Acad. Sci. USA. 1995;92:4507–4511
  25. Haldar S, Chintapalli J, Croce CM. Taxol induced Bcl-2 phosphorylation and death in prostate cancer cells. Cancer Res. 1996;56:1253–1255
  26. Griffon-Etienne G, Boucher Y, Brekken C, Suit HD, Jain RK. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res. 1999;59:3776–3782
  27. Liekens S, De Clercq E, Neyts J. Angiogenesis: regulators and clinical applications. Biochem. Pharmacol. 2001;61:253–270
  28. Kirsch M, Schackert G, Black PM. Angiogenesis, metastasis, and endogenous inhibition. J. Neurooncol. 2000;50:173–180
  29. Netti PA, Hamberg LM, Babich JW, et al.  Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules. Proc. Natl. Acad. Sci. USA. 1999;96:3137–3142
  30. Rosen L. Antiangiogenic strategies and agents in clinical trials. Oncologist. 2000;5(Suppl 1):20–27
  31. Sweeney CJ, Miller KD, Sissons SE, et al.  The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res. 2001;61:3369–3372
  32. Vacca A, Ribatti D, Iurlaro M, et al.  Docetaxel versus paclitaxel for antiangiogenesis. J. Hematother. Stem Cell Res. 2002;11(1):103–118
  33. Saaristo A, Karpanen T, Alitalo K. Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene. 2000;19:6122–6129
  34. Linderholm BK, Lindh B, Beckman L, et al.  The prognostic value of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) and associations to first metastasis site in 1307 patients with primary breast cancer. Proc. Am. Soc. Clin. Oncol. 2001;20:13
  35. Moos PJ, Fitzpatrick FA. Taxane-mediated gene induction is independent of microtubule stabilization: induction of transcription regulators and enzymes that modulate inflammation and apoptosis. Proc. Natl. Acad. Sci. USA. 1998;95:3896–3901
  36. Synold TW, Dussault I, Forman BM. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat. Med. 2001;7:584–590
  37. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol. Ther. 1999;82:241–250
  38. Nagy P, Jenei A, Damjanovich S, Jovin TM, Szöllôsi J. Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy. Pathol. Oncol. Res. 1999;5:255–271
  39. Wikstrand CJ, Bigner DD. Prognostic applications of the epidermal growth factor receptor and its ligand, transforming growth factor-α. J. Natl. Cancer Inst. 1998;90:799–801
  40. Grandis JR, Melhem MF, Gooding WE, et al.  Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival. J. Natl. Cancer Inst. 1998;90:824–832
  41. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur. J. Cancer. 2001;37(Suppl 4):9–15
  42. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–182
  43. Tiwari RK, Borgen PI, Wong GY, Cordon-Cardo C, Osborne MP. HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis. Anticancer Res. 1992;12:419–425
  44. Johnston SR, Kelland LR. Farnesyl transferase inhibitors – a novel therapy for breast cancer. Endocr. Relat. Cancer. 2001;8:227–235
  45. Smith CA, Pollice AA, Gu LP, et al.  Correlations among p53, HER2/neu and ras overexpression and aneuploidy by multiparameter flow cytometry in human breast cancer; evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas. Clin. Cancer Res. 2000;6:112–126
  46. Theillet C, Lidereau R, Escot C. Frequent loss of H-ras allele correlates with aggressive human primary breast carcinomas. Cancer Res. 1986;46:4776–4781
  47. Kato K, Cox AD, Hisaka MM, Graham SM, Buss JE, Der CJ. Isoprenoid addition to ras protein is the critical modification for its membrane association and transforming activity. Proc. Natl. Acad. Sci. USA. 1992;89:6403–6407
  48. Johnson DH, DeVore R, Kabbinavar F, Herbst R, Holmgren E, Novotny W. Carboplatin (C)+paclitaxel (T)+RhuMab-VEGF (AVF) may prolong survival in advanced non-squamous lung cancer. Proc. Am. Soc. Clin. Oncol. 2001;20:1256
  49. Baselga J. Clinical trials of Herceptin® (trastuzumab). Eur. J. Cancer. 2001;37(Suppl. 1):18–24
  50. Sparano JA. Cardiac toxicity of trastuzumab (Herceptin): implications for the design of adjuvant trials. Semin. Oncol. 2001;28(Suppl. 3):20–27
  51. Pegram MD. Docetaxel and herceptin: foundation for future strategies. Oncologist. 2001;6(Suppl 3):22–25
  52. Slamon D, Pegram M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin. Oncol. 2001;28(Suppl 3):13–19
  53. Kuzur ME, Albain KS, Huntington MO, et al.  A phase II trial of docetaxel and Herceptin in metastatic breast cancer patients overexpressing HER-2. Proc. Am. Soc. Clin. Oncol. 2000;19:512
  54. Burris 3rd HA. Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer. Semin. Oncol. 2001;28(Suppl 3):38–44
  55. Uber KA, Nicholson BP, Thor AD, et al.  A phase II trial of weekly docetaxel (D) and herceptin (H) as first- or second-line treatment in HER2 overexpressing metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 2001;20:1949
  56. Esteva FJ, Valero V, Booser D, et al.  Phase II study of weekly docetaxel and trastuzumab for patients with HER-2 overexpressing metastatic breast cancer. J. Clin. Oncol. 2002;20:1800–1808
  57. Meden H, Beneke A, Hesse T, Novophashenny I, Wischnewsky M. Weekly intravenous recombinant humanized anti-P185HER2 monoclonal antibody (Herceptin) plus docetaxel in patients with metastatic breast cancer: a pilot study. Anticancer Res. 2001;21:1301–1305
  58. Nabholtz JM, Pienkowski T, Northfelt D, et al.  Results of two open label multicentre phase II pilot studies with Herceptin in combination with docetaxel and platinum salts (cis or carboplatin) (TCH) as therapy for advanced breast cancer (ABC) in women with tumours overexpressing the HER2-neu proto-oncogene. Eur. J. Cancer. 2001;37(Suppl 6):190
  59. Pienkowski T, Fumuleau P, Eiermann W, et al.  Taxotere, cisplatin and Herceptin (TCH) in first-line HER-2 positive metastatic breast cancer (MBC) patients: a phase II pilot study by the Breast Cancer International Research Group (BCIRG 101). Proc. Am. Soc. Clin. Oncol. 2001;20:2030
  60. Slamon DJ, Patel R, Northfelt D, et al.  Phase II pilot study of Herceptin combined with Taxotere and carboplatin (TCH) in metastatic breast cancer (MBC) patients overexpressing the HER-2-neu proto-oncogene: a pilot study of the UCLA Network. Proc. Am. Soc. Clin. Oncol. 2001;20:193
  61. Herbst RS, Langer CJ. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin. Oncol. 2002;29(1 Suppl 4):27–36
  62. Ciardiello F. Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents. Drugs. 2000;60(Suppl 1):25–32
  63. Raymond E, Faivre S, Armand JP. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs. 2000;60(Suppl 1):15–23
  64. Baselga J. The EGFR as a target for anticancer therapy – focus on cetuximab. Eur. J. Cancer. 2001;37(Suppl 4):16–22
  65. Kim ES, Mauer AM, Fossella FV, et al.  A phase II study of Erbitux (IMC-C225), an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 2002;21:1168
  66. Moasser MM, Sepp-Lorenzino L, Kohl NE, et al.  Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc. Natl. Acad. Sci. USA. 1998;95:1369–1374
  67. Khuri FR, Glisson BS, Meyers ML, et al.  Phase I study of farnesyl transferase inhibitor (FTI) SCH66336 with paclitaxel in solid tumours: dose finding, pharmacokinetics, efficacy/safety. Proc. Am. Soc. Clin. Oncol. 2000;19:799
  68. Piccart MJ, Branle F, de Valeriola M, et al.  A phase I, clinical and pharmacokinetic (PK) trial of the Farnesyl Transferase Inhibitor (FTI) R115777+Docetaxel: a promising combination in patients (PTS) with solid tumours. Proc. Am. Soc. Clin. Oncol. 2001;20:318
  69. Fujimoto-Ouchi K, Tanaka Y, Tominaga T. Schedule dependency of antitumor activity in combination therapy with capecitabine/5’-deoxy-5-fluorouridine and docetaxel in breast cancer models. Clin. Cancer Res. 2001;7:1079–1086
  70. O’Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub J-P, Cervantes G, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J. Clin. Oncol. 2002;20(12):2812–2823
  71. Leonard R, Cervantes G, Lui W-Y, et al.  Survival update of SO14999 – a large phase III trial of capecitabine/docetaxel combination therapy vs docetaxel monotherapy in patients with locally advanced (LABC) or metastatic breast cancer (MBC). Eur. J. Cancer. 2001;37(Suppl 6):151
  72. Pagani O, Sessa C, Longhi S, et al.  Dose-finding study of docetaxel (T) and doxorubicin (A) day 1 and 8 plus capecitabine (X) day 1 to 14 (TAX) as first line treatment in advanced breast cancer (ABC). Eur. J. Cancer. 2001;37(Suppl 6):194
  73. Khuri FR, Kurie JM. Antisense approaches enter the clinic. Clin. Cancer Res. (Ed.). 2000;6(5):1607–1610
  74. Waters JS, Webb A, Cunningham D, et al.  Phase I clinical and pharmacokinetic study of Bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin’s lymphoma. J. Clin. Oncol. 2000;18:1812–1823
  75. Hayes DF, Chen, HX, Marshall JL, Lippman D, Figuera M, Fingert H. G3139 (oligonucleotide antisense against bcl-2) and docetaxel in patients with Bcl-2-positive malignancies. In: American Society of Clinical Oncology, 37th Annual Meeting; 12–15 May 2001; San Francisco, CA, USA. Symposium: beyond chemotherapy – emerging targeted therapies for the treatment of cancer
  76. Morris MJ, Tong WP, Cordon-cardo C, et al.  BCL-2 antisense (G3139) plus docetaxel for treatment of progressive androgen-independent prostate cancer. Eur. J. Cancer. 2001;37(Suppl 6):218
  77. McMahon G. VEGF receptor signaling in tumor angiogenesis. Oncologist. 2000;5(Suppl 1):3–10

PII: S0305-7372(03)00097-5

doi: 10.1016/S0305-7372(03)00097-5

Cancer Treatment Reviews
Volume 29, Issue 5 , Pages 407-415 , October 2003

Article Tools

* Image Usage & Resolution